Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), Bolt Biotherapeutics's 3-1 Month Momentum % is N/A%.
The industry rank for Bolt Biotherapeutics's 3-1 Month Momentum % or its related term are showing as below:
FRA:6LP0's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -7.65 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Bolt Biotherapeutics 3-1 Month Momentum % Related Terms
FRA:6LP0 vs PCSA, BRTX, LIMN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Bolt Biotherapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bolt Biotherapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics (FRA:6LP0) has a 3-1 Month Momentum % of N/A% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bolt Biotherapeutics and its competitors. According to the industry distribution chart, Bolt Biotherapeutics ranks #955 out of 1389 companies in the Biotechnology industry, placing it in the top 68.8%.
Is Bolt Biotherapeutics' 3-1 Month Momentum % too high?
Bolt Biotherapeutics' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Bolt Biotherapeutics ranks #955 out of 1389 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bolt Biotherapeutics has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' 3-1 Month Momentum % compare to PCSA and BRTX?
According to the Biotechnology industry distribution chart, Bolt Biotherapeutics ranks #955 out of 1389 companies for 3-1 Month Momentum %. This places Bolt Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bolt Biotherapeutics and its competitors. Bolt Biotherapeutics's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Bolt Biotherapeutics (FRA:6LP0) has a current 3-1 Month Momentum % of N/A%. The stock's GF Value™ is €11.84, compared to a current price of €5.18 — trading 56.3% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. Bolt Biotherapeutics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Bolt Biotherapeutics (FRA:6LP0), the current 3-1 Month Momentum % is N/A% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bolt Biotherapeutics (FRA:6LP0) Overvalued in 2026?
Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued.
The current stock price of €5.18 is trading 56.3% below its estimated GF Value™ of €11.84.
Key valuation signals for FRA:6LP0:
3-1 Month Momentum %: N/A%
GF Value™: €11.84 vs. price of €5.18 (56.3% below fair value)
No single metric tells the full story. See the FRA:6LP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
53GF Score
Get the complete analysis for FRA:6LP0
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6LP0 has been successfully added to your 
